Editor's note

This article was originally published on 10 September 2014 as part of the VacZine Analytics ExpertREACT series. It is reproduced here for archival purposes. Market conditions, pipeline statuses and regulatory positions described reflect the state of knowledge at that date.

New antibiotics - exciting but not novel classes

Four new antibiotics reached the US market in the period leading up to the 54th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC): Orbactiv™ (oritavancin), Sivextro™ (tedizolid), Teflaro™ (ceftaroline) and Dalvance™ (dalbavancin). Whilst welcome, these are not new drug classes and carry a predominantly Gram-positive rather than the critically needed Gram-negative bias. The Keynote address by John Rex (AstraZeneca) reignited debate about whether the economics of antibiotic development are sufficiently attractive to sustain innovation, particularly for novel classes targeting multi-drug resistant organisms.

A speaker at ICAAC asked: "Why can't antibiotics cost the ~$75,000 per course to save a life, similar to novel cancer and antiviral therapies?" The days of large pharmaceutical antibiotic giants - GSK, Pfizer and Johnson & Johnson - have largely passed, leaving the field to smaller players such as Cubist Pharmaceuticals.

HIV and HCV: the power of economic incentives

By contrast, the economics of HIV and HCV antivirals have driven extraordinary progress. HIV can now be managed with highly effective single-tablet fixed-dose combinations pioneered by Gilead (Atripla®/Complera®/Stribild®). ViiV Healthcare's Tivicay (dolutegravir) - an integrase inhibitor now also available as Triumeq - was described at ICAAC as approaching "wonderdrug" status due to its high barrier to resistance. In HCV, sofosbuvir (Sovaldi®) had revolutionised treatment and even the stringent UK NICE committee had provisionally approved it given downstream cost savings from avoided liver transplantation.

"It simply does not make any sense that a death from a bacterium should be worth less to us than that from a virus."

Vaccines - underfunded but making progress

Vaccines were not centre stage at ICAAC. GSK, Pfizer and Sanofi Pasteur did not even have exhibitor stands. Notable discussions covered pertussis resurgence - with the UK's maternal Repavax programme showing good safety signals - and maternal vaccine strategies for RSV (Novavax preclinical data in baboons) and CMV (VBI Vaccines). One industry executive told VacZine Analytics that in the US, it had been two years since Series A funding was granted to a biotech focused solely on prophylactic vaccination.

Series A Drought
2 yrs

Time since last Series A funding for a US prophylactic vaccine-only biotech, as cited by an industry executive at ICAAC 2014